This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Pharmacokinetics of anidulafungin (Ecalta �) given...
Clinical trial

Pharmacokinetics of anidulafungin (Ecalta �) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who

Read time: 1 mins
Last updated:24th Aug 2010
To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h) to patients undergoing an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or receiving intensive chemotherapy for AML-MDS
Category Value
Study start date 2010-08-24

View full details